ProCE Banner Activity

MATTERHORN: Interim Results From a Phase III Trial of Durvalumab + FLOT in Resectable Gastric and Gastroesophageal Junction Cancer

Conference Coverage
Slideset

In the phase III MATTERHORN trial, the addition of durvalumab to perioperative FLOT in patients with gastric and gastroesophageal junction cancer was associated with a significant improvement in pCR rate.

Released: October 25, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc